Leohr J, Kazda C, Liu R, et al. - According to this 2-part, randomized, double-blind Phase 1b study, when compared with Humalog, ultra rapid lispro (URLi) demonstrated accelerated insulin lispro absorption and greater postprandial glucose reduction at different meal-to-dose timings, and it was well tolerated in patients with type 2 diabetes mellitus (T2D).

• When compared with Humalog, URLi increased insulin exposure within the first 30 minutes postdose by 2.2-fold and decreased time to early half-maximal drug concentration by 22.6%.

• When taken before, immediately before, or after a meal, URLi resulted in better postprandial glucose lowering.

• When the same meal-to-dose timing was used for both insulins, the postprandial glucose excursion over 5 hours was reduced by 29-105% with URLi for all three dose timings (-15 minutes, 0 minutes, and +15 minutes).

• In patients with T2D, the pharmacokinetics and glucodynamics were maintained after 2 weeks of daily subcutaneous dosing.

• During the mixed meal tolerance tests, URLi had more hypoglycemic events; both treatments had few events during the 2-week outpatient dosing period.